Evolution of adjuvant therapy for NSCLC from 2014 to 2024

Authors

DOI:

https://doi.org/10.24866/3033-5485/2025-1/55-61

Keywords:

non-small cell lung cancer, adjuvant chemotherapy, adjuvant targeted therapy, adjuvant immunotherapy

Abstract

Lung cancer is a relevant oncological disease with a high incidence rate and relatively modest treatment results. For a long time, adjuvant chemotherapy remained the only drug option for adjuvant treatment of patients with non-small cell lung cancer (NSCLC) stages IB–IIIA. The necessity to discover new approaches to the adjuvant treatment of NSCLC is certainly associated with low overall survival results and a high risk of lung cancer relapse after chemotherapy alone. In the course of the evolution of knowledge about tumor biology, molecular mechanisms of cancer development and spread, two new areas of adjuvant therapy have emerged - targeted and immunotherapy. This review discusses phase III studies, the results of which demonstrated improved survival rates in patients who received innovative adjuvant therapy, which made it possible to introduce new options for adjuvant therapy for NSCLC into clinical practice. The timeframes for the implementation of these options in practical recommendations are also reflected.

Author Biographies

  • Viktor V. Kondratyev, Sakhalin Regional Clinical Oncological Dispensary; Pacific State Medical University

    Oncologist, Department of Thoracic Oncology; Assistant, Department of Oncology

  • Vladimir I. Apanasevich, Pacific State Medical University

    Doctor of Medical Sciences, Professor of the Institute of Surgery

  • Sergey S. Startsev, Sakhalin Regional Clinical Oncological Dispensary; Pacific State Medical University

    Chief Physician; Lecturer, Department of Oncology

  • Inessa S. Usoltseva, Sakhalin Regional Clinical Oncological Dispensary; Pacific State Medical University

    Oncologist, Department; Assistant, Department of Oncology

  • Aleksey B. Sunyaykin, Sakhalin Regional Clinical Oncological Dispensary; Pacific State Medical University

    Oncologist, Department; Assistant, Department of Oncology

  • Olga S. Plotnikova, Primorsky Regional Oncology Dispensary; Pacific State Medical University

    Radiotherapist; Assistant, Institute of Surgery

References

1. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Москва: Изд-во МНИОИ им. П.А. Герцена, 2022. 252 с. = Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow, Moscow Research Oncology Institute named after P.A. Herzen, 2022, 252 p. (In Russ.).

2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin, 2014, vol. 64, no. 1, pp. 9–29. DOI: https://doi.org/10.3322/caac.21208

3. Usami N., Yokoi K., Hasegawa Y., Taniguchi H., Shindo J., Yamamoto M, Suzuki R., Imaizumi K., Kondo M., Shimokata K. Phase II study of carboplatin and gemcitabine as adju-vant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. Int J Clin Oncol, 2010, vol. 15, no. 6, pp. 583–587. DOI: https://doi.org/10.1007/s10147-010-0118-x

4. Zhang L., Ou W., Liu 0., Li N., Liu L., Wang S. Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer. Thorac Cancer, 2014, vol. 5, no. 1, pp. 50–56. DOI: https://doi.org/10.1111/1759-7714.12058

5. Laktionov K.K., A.M. Kazakov, E. Reutova, M.S. Ardzinba, A.L. Arzumanian. Prospects for the development of adjuvant therapy for non-small cell lung cancer. Journal of Modern Oncology, 2020, vol. 22, no. 3, pp. 85–87. DOI: https://doi.org/10.26442/18151434.2020.3.200339

6. Alam N., Shepherd F.A., Winton T. et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer, 2005, vol. 47, no. 3, pp. 385–394. DOI: https://doi.org/10.1016/j.lungcan.2004.08.016

7. Herbst R.S., Wu Y., John T., Grohe C., Majem M., Wang J., Kato T., Goldman J.W., Laktionov K.K., Kim S., Yu C., Vu H.V., Lu S., Lee K.Y., Mukhametshina G., Akewanlop C., Marinis F., Bonanno L., Domine M., Shepherd F.A., Urban D., Huang X., Bolanos A., Stachowiak M., Tsuboi M. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB–IIIA Non-Small-Cell Lung Cancer: Updated Results from the Phase III Randomized ADAURA Trial. J Clin Oncol, 2023, vol. 41, no. 10, pp. 1830–1840. DOI: https:/doi.org/10.1200/JCO.22.02186

8. Solomon B.J., Ahn J.S., Dziadziuszko R., Barlesi F., Nishio M., Lee D.H., Zhong W., Hori-nouchi H., Mao W., Hochmair M.J., Marinis F., Migliorino M.R., Bondarenko I., Lohmann T.O., Xu T., Cardona Gavaldon A., Bordogna W., Ruf T., Wu Y. Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer. Annals of Oncology, 2023, vol. 34, no. 2, pp. 1254–1335. DOI: https://doi.org/10.1016/S0923-7534(23)04149-2

9. Wakelee H.A, Altorki N.K., Zhou C., Csőszi T., Vynnychenko I.O., Goloborodko O., Rittmeyer A., Reck M., Martinez-Marti A., Kenmotsu H., Chen Y., Chella A., Sugawara S., Fu C., Ballinger M., Deng Y., Srivastava M.K., Bennett E., Gitlitz B.J., Felip E. IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB–IIIA non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2024, vol. 42, no. 17. DOI: https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA8035

10. O'Brien M., Paz-Ares L., Marreaud S., Dafni U., Oselin K., Havel L., Esteban E., Isla D., Mar-tinez-Marti A., Faehling M., Tsuboi M., Lee J., Nakagawa K., Yang J., Samkari A., Keller S.M., Mauer M., Jha N., Stahel R., Besse B., Peters S. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol, 2022, vol. 23, no. 10, pp. 1274–1286. DOI: https://doi.org/10.1016/S1470-2045(22)00518-6

11. Wu Y., Hu L., Zhang S., Zhang H. The value of perioperative immunotherapy for non-small cell lung cancer: a pool- and meta-analysis. Technology in Cancer Research & Treatment, 2024, vol. 23. DOI: https://doi.org/10.1177/15330338241258164

12. Wang J., Wu Y., Lu S., Wang Q., Li S., Zhong W., Wang Q., Li W., Wang B., Chen J., Cheng Y., Duan H., Li G., Shan L., Liu Y., Liu J., Huang X., Bolanos A., He J. Adjuvant Osimertinib in patients with stage IB to IIIA EGFR mutation-positive NSCLC after complete tumor resection: ADAURA China subgroup analysis. JTO Clinical and Research Reports, 2024, vol. 5, no. 2. DOI: https://doi.org/10.1016/j.jtocrr.2023.100621

13. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2013 году. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. 235 с. = Kaprin A.D., Starinskiy V.V., Petrova G.V. The state of cancer care for the population of Russia in 2013. Moscow, Moscow Research Oncology Institute named after P.A. Herzen, 2014, 235 p. (In Russ.).

14. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2023 году. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2024. 262 с. = Kaprin A.D., Starinskiy V.V., Petrova G.V. The state of cancer care for the population of Russia in 2023. Moscow, Moscow Research Oncology Institute named after P.A. Herzen, 2024, 262 p. (In Russ.).

Downloads

Published

2025-02-20

Issue

Vol. 1 No. 1 (2025)

Section

ONCOLOGY, RADIATION THERAPY

License

Copyright (c) 2025 Виктор Валерьевич Кондратьев, Владимир Иосифович Апанасевич, Сергей Станиславович Старцев, Инесса Станиславовна Усольцева, Алексей Борисович Суняйкин, Ольга Сергеевна Плотникова

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Evolution of adjuvant therapy for NSCLC from 2014 to 2024. (2025). Clinical and Fundamental Medicine, 1(1), 55-61. https://doi.org/10.24866/3033-5485/2025-1/55-61

Most read articles by the same author(s)